Royalty Pharma Announces Greg Norden Joins Investment Committee
NEW YORK, Jan. 15, 2015 /PRNewswire/ -- Royalty Pharma is pleased to announce that Greg Norden has joined its Investment Committee.
Greg brings more than 25 years of leadership experience in financial management and more than 20 years of experience in global healthcare and pharmaceuticals. Greg is currently the Managing Director of G9 Capital Group, LLC, which invests in early stage ventures and provides corporate advisory services. From 1989 to 2010, Greg held various senior positions with Wyeth, most recently as its Senior Vice President and Chief Financial Officer. At Wyeth, Greg was a key member of the primary management and operating committees, Chairman of the Investment Committee and Disclosure Committee, Co-Chairman of the Capital Committee, and an executive member of the R&D Executive Development Council and M&A Committee. Greg started his career in 1983 with Arthur Andersen & Company working primarily with multi-national public and private companies in the Consumer Products and Financial Services industries.
"Greg's financial expertise and industry knowledge will add a valuable and important perspective to the Investment Committee and we are looking forward to benefit from his insights," said Pablo Legorreta, Founder & Chief Executive Officer of Royalty Pharma.
Greg currently serves on several Boards including: Zoetis, a global leader in discovering, developing, manufacturing and commercializing animal health medicines and vaccines, where he is Chairman of the Audit Committee and Member of the Compensation Committee; NanoString Technologies, a provider of life science tools for translational research and development of molecular diagnostic products where he is Chairman of the Audit Committee; Welch Allyn, a leading global provider of medical diagnostic equipment, where he is Chairman of the Audit Committee and Member of the Nominating and Governance Committee. Greg is also a former Board member of Human Genome Sciences serving as Chairman of the Audit Committee until GlaxoSmithKline acquired the company in 2012.
Greg received his B.S. in Management/Economics, Magna Cum Laude from State University of New York–Plattsburgh, his M.S. in Accounting from Long Island University – C. W. Post, and is a licensed CPA in the State of New York.
About Royalty Pharma
Royalty Pharma is the industry leader in the acquisition of revenue-producing intellectual property with over $12 billion in royalty assets – principally royalty interests in leading pharmaceutical and biotechnology products. Royalty Pharma provides liquidity to holders of interests in revenue-producing intellectual property in approved biopharmaceutical products, and finances the clinical development of biopharmaceutical products in exchange for a royalty interest. Royalty Pharma owns royalty interests in 51 marketed and late stage biopharmaceutical products, including Abbott's Humira®, J&J's Remicade® and Prezista®, Gilead's Atripla®, Truvada®, Complera® and Stribild®, Pfizer's Lyrica®, Merck's Januvia/Janumet®, Biogen Idec's Tecfidera®, Pharmacyclics' and J&J's Imbruvica®, Vertex Kalydeco® and other cystic fibrosis products, Roche's Mircera®, and UCB's Cimzia®, among others. Additional company information is available at www.royaltypharma.com.
Royalty Pharma | RP Management LLC
Investor Relations & Public Affairs
+ 1 (212) 883-0200
[email protected]
Logo - http://photos.prnewswire.com/prnh/20130812/NY62264LOGO
SOURCE Royalty Pharma
Share this article